Search
Powered By HealthLine
Health Tools
 PSA Test
 The Basics of the Prostate
 Prostate Q&A
 Basics of Erectile Dysfunction
 Tips For Men's Sexual Health
Featured Conditions
 Erectile Dysfunction
 Prostate
 Heart
 Diet & Exercise
Resources
Healthscout News
3D Health Animations
Health Videos
Quizzes & Tools
Health Encyclopedia
In-Depth Reports
Library & Communities
News Archive
Drug Library
Find a Therapist
Enter City or Zip Code:
Powered by Psychology Today
PR Newswire
 Read latest







Channels
Home |  Today | Women| Men| Kids| Seniors| Diseases| Addictions| Sex & Relationships| Diet, Fitness, Looks| Alternative Medicine| Drug Checker
 Printer Friendly  Send to a Friend

Prostate Screening Under Fire

Ivanhoe Broadcast News


Related Encyclopedia
 border=
Ankylosing Spondylitis
Baldness
Bechterew's Disease (Ankylosing spondylitis)
Benign Prostatic Hyperplasia
More...

Related Healthscout Videos
 border=
Don't Wait on Your Prostate
The Rise of Cancer
Doubling Prostate Cancer Survival
HPV: The New Kissing Disease?
More...

Related Animations
 border=
Erectile Dysfunction
More...

Related Drug Information
 border=
Cialis
Flomax
Topamax
Viagra
More...

Related News Articles
 border=
1 in 5 Pharmacies Hinders Teens' Access to 'Morning-After' Pill: Study
Understanding the Genetics of Colon Cancer
Hops may Prevent Prostate Cancer
H1N1 Deaths Comparable to Seasonal Flu
More...

(Ivanhoe Newswire) Finding cancers early is a good thing, right? Usually, yes. But when it comes to prostate cancer, researchers are now suggesting some cancers might be better left unknown.

In a review of two large studies on prostate cancer screening with the PSA blood test, investigators from the American Cancer Society and University of Texas Health Science Center at San Antonio note while screening is picking up more cancers, many of those cancers are clinically insignificant.

Text Continues Below



Specifically, they note computer modeling shows 29 percent of prostate cancers diagnosed in whites and 44 percent diagnosed in blacks fall into the over diagnosis category, meaning these men would probably never suffer any ill effects from the cancers.

Writing in an accompanying editorial, fellow investigators agree, citing statistics showing the average American man had an 8.7 percent lifetime risk of being diagnosed with prostate cancer before the PSA test was introduced in the mid-80s. By 2005, that risk doubled to 17 percent. But the risk of death from prostate cancer remained relatively stable the average man had a 2.5 percent lifetime risk of dying from the disease prior to widespread use of the PSA test versus a 3 percent risk in 2005.

Because many prostate cancers will never progress to the deadly stage, and treatment for prostate cancer can have significant adverse effects on men, including incontinence and sexual dysfunction, they suggest men should carefully weigh the value of PSA testing with their doctors.

The real impact and tragedy of prostate cancer screening is the doubling of the lifetime risk of a diagnosis of prostate cancer with little if any decrease in the risk of dying from this disease, they conclude.

SOURCE: CA: A Cancer Journal for Clinicians, published online June 29, 2009



If this story or any other Ivanhoe story has impacted your life or prompted you or someone you know to seek or change treatments, please let us know by contacting Melissa Medalie at mmedalie@ivanhoe.com

This article was reported by Ivanhoe.com, who offers Medical Alerts by e-mail every day of the week. To subscribe, go to: http://www.ivanhoe.com/newsalert/.




Last updated 7/1/2009 10:00:00 AM

Related Links
 border=
From Healthscout's partner site on erectile dysfunction, ErectileDysfunctionConnection.com
SELF-TEST: Test your ability to achieve an erection
HOME REMEDY: Treat ED with herbs and supplements
DRUGS: Common drugs used to treat impotence





HealthScout is a part of HealthCentral
About Us   Our Blog   Contact Us   Privacy Policy   Terms of Use   Site Map  
Copyright © 2001-2013. The HealthCentralNetwork, Inc. All rights reserved.
Advertising Policy   Editorial Policy Advertise With Us   Anti-Spam Policy   PR Newswire